Immunoglobulin, Antibody, Or Fragment Thereof, Other Than Immunoglobulin Antibody, Or Fragment Thereof That Is Conjugated Or Adsorbed Patents (Class 530/387.1)
  • Patent number: 10732182
    Abstract: The present invention relates to methods of determining cancer cell sensitivity to treatment by using antibodies that specifically bind to and detect the presence of a Bcl-2 heterodimer protein, or a caspase and an inhibitor of caspase-IAP heterodimer protein in the cell. The methods provide a predictive tool to identify patients likely to respond to drugs that perturb heterodimer binding and induce apoptosis in a cancer cell. The invention also provides a method of predicting therapeutic efficacy in a cancer patient.
    Type: Grant
    Filed: August 1, 2014
    Date of Patent: August 4, 2020
    Assignee: Eutropics Pharmaceuticals, Inc.
    Inventor: Michael H. Cardone
  • Patent number: 10722569
    Abstract: Some aspects of this disclosure provide engineered exopolysaccharide-associated proteins, engineered bacteria expressing such proteins, and engineered biofilms comprising such proteins. Some aspects of this disclosure provide methods for engineering exopolysaccharide-associated proteins, and for the generation of engineered bacteria and biofilms expressing or comprising such proteins. Some aspects of this disclosure provide compositions and methods useful for the generation of vaccines and the vaccination of subjects, for delivering molecules of interest to a target site, for example, a surface, for purification of molecules of interest, for example, from bioreactors comprising engineered bacteria as provided herein, and for bioremediation applications, such as the cleanup of environmental pollutants.
    Type: Grant
    Filed: July 3, 2013
    Date of Patent: July 28, 2020
    Assignee: Children's Medical Center Corporation
    Inventor: Paula I. Watnick
  • Patent number: 10676528
    Abstract: The invention provides a chimeric antigen receptor (CAR) comprising an antigen binding domain specific for TSLPR, a transmembrane domain, and an intracellular T cell signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of a proliferative disorder, e.g., cancer, in a mammal and methods of treating or preventing a proliferative disorder, e.g., cancer, in a mammal are also disclosed.
    Type: Grant
    Filed: October 30, 2014
    Date of Patent: June 9, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Haiying Qin, Terry J. Fry
  • Patent number: 10668149
    Abstract: The present invention relates to combination therapies for heme malignancies with anti-CD38 antibodies and survivin inhibitors.
    Type: Grant
    Filed: June 22, 2016
    Date of Patent: June 2, 2020
    Assignee: Janssen Biotech, Inc.
    Inventors: Parul Doshi, Henk M. Lokhorst, Tuna Mutis
  • Patent number: 10670604
    Abstract: The present invention belongs to the field of immunology and molecular biology, which relates to an anti-PCSK9 antibody, the pharmaceutical composition and method of use thereof. In particular, the present invention relates to the monoclonal antibody, which can bind PCSK9 specifically, block association of PCSK9 with LDLR, upregulate the amount of LDLR on cell surface, heighten the metabolism of LDL cholesterol and/or triglycerides, and prevent/treat cardiovascular diseases caused by hypercholesterolemia.
    Type: Grant
    Filed: February 4, 2016
    Date of Patent: June 2, 2020
    Assignee: AD Pharmaceutical Co., Inc.
    Inventors: Baiyong Li, Zhongmin Wang, Yu Xia, Peng Zhang, Wuxian Ren, Jinan Jiao, Yuanyuan Xu, Dongsheng Dai
  • Patent number: 10653791
    Abstract: Provided herein are heavy chain constant regions (referred to as “modified heavy chain constant regions”), or functionally equivalent fragments thereof, that enhance biological properties of antibodies relative to the same antibodies in unmodified form. An exemplary modified heavy chain constant region includes an IgG2 hinge and three constant domains (i.e., CH1, CH2, and CH3 domains), wherein one or more of the constant region domains are of a non-IgG2 isotype (e.g., IgG1, IgG3 or IgG4). The heavy chain constant region may comprise wildtype human IgG domain sequences, or variants of these sequences. Also provided herein are methods for enhancing certain biological properties of antibodies that comprise a non-IgG2 hinge, such as internalization, agonism and antagonism, wherein the method comprises replacing the non-IgG2 hinge of the antibody with an IgG2 hinge.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: May 19, 2020
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Nils Lonberg, Alan J. Korman, Mark J. Selby, Bryan C. Barnhart, Aaron P. Yamniuk, Mohan Srinivasan, Karla A. Henning, Michelle Minhua Han, Ming Lei, Liang Schweizer, Sandra V. Hatcher, Arvind Rajpal
  • Patent number: 10640574
    Abstract: The present disclosure provides humanized antibodies, including antibodies comprising an ultralong CDR3 and uses thereof.
    Type: Grant
    Filed: July 18, 2014
    Date of Patent: May 5, 2020
    Assignee: Taurus Biosciences, LLC
    Inventors: Omar Bazirgan, Miguel De Los Rios
  • Patent number: 10618964
    Abstract: The present invention relates to amino acid sequences that are directed against/and or that can specifically bind (as defined herein) Interleukin-6 Receptor (IL-6R), as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. In a specific aspect, the present invention provides amino acid sequences and polypeptides that are capable of binding to two or more different antigenic determinants, epitopes, parts, domains of IL-6R, also referred to as “multiparatopic” (such as e.g. “biparatopic” or “triparatopic”, etc.) amino acid sequences and polypeptides.
    Type: Grant
    Filed: April 12, 2010
    Date of Patent: April 14, 2020
    Assignee: Ablynx N.V.
    Inventors: Veerle Compernolle, Francis Descamps
  • Patent number: 10562975
    Abstract: A method of treating a T-cell mediated disease in a subject by administering to the subject a therapeutically effective amount of an antibody or fragment thereof that specifically binds to CD6 is described. Humanized antibodies useful for the method are also described.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: February 18, 2020
    Assignees: THE REGENTS OF THE UNIVERSITY OF MICHIGAN, THE CLEVELAND CLINIC FOUNDATION
    Inventors: Feng Lin, David A. Fox
  • Patent number: 10561653
    Abstract: The present invention relates to 5-bromo-2,6-di-(1H-pyrazol-1-yl)pyrimidin-4-amine, its pharmaceutically acceptable salts and co-crystals thereof and to pharmaceutical compositions comprising said compounds for use in the treatment of cancer.
    Type: Grant
    Filed: August 10, 2016
    Date of Patent: February 18, 2020
    Assignees: Novartis AG, Palobiofarma, S.L.
    Inventors: Sanela Bilic, Juan Alberto Camacho Gomez, John Scott Cameron, Julio Cesar Castro-Palomino Laria, Danny Roland Howard, Jr.
  • Patent number: 10556954
    Abstract: Provided in the present invention are a type of anti-human PD-L1 specific nanobodies and VHH chains thereof, coding sequences of the foregoing nanobodies or VHH chains thereof, corresponding expression vectors and host cells, and a method for producing antibodies.
    Type: Grant
    Filed: March 17, 2017
    Date of Patent: February 11, 2020
    Assignee: NANOMAB TECHNOLOGY LIMITED
    Inventors: Hong Hoi Ting, Chung Lim Wong
  • Patent number: 10555713
    Abstract: The present invention relates to methods and medicaments useful for treating idiopathic pulmonary fibrosis (IPF) by administering anti-CTGF antibodies. Methods for prognosing individuals with IPF are also provided.
    Type: Grant
    Filed: July 5, 2018
    Date of Patent: February 11, 2020
    Assignee: FIBROGEN, INC
    Inventors: Seth Porter, John L. Stauffer
  • Patent number: 10550189
    Abstract: The present invention relates to anti-interleukin-36R (anti-IL-36R) binding compounds, in particular new anti-IL-36R antibodies and therapeutic and diagnostic methods and compositions for using the same.
    Type: Grant
    Filed: April 1, 2015
    Date of Patent: February 4, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Su-Ellen Brown, Keith Canada, Lukasz Chlewicki, Michael Howell, Detlev Mennerich, Joseph Robert Woska, Jr.
  • Patent number: 10544221
    Abstract: Disclosed herein are single chain variable fragment CD3 binding proteins with improved binding affinities, and robust aggregation profiles. Also described are multispecific binding proteins comprising a single chain variable fragment CD3 binding protein according to the instant disclosure. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are provided.
    Type: Grant
    Filed: May 19, 2017
    Date of Patent: January 28, 2020
    Assignee: HARPOON THERAPEUTICS, INC.
    Inventors: Robert B. Dubridge, Pui Seto, Richard J. Austin, Luke Evnin, Jeanmarie Guenot, Bryan D. Lemon
  • Patent number: 10538549
    Abstract: NNA-derived specific adducts represent an integrated biomarker of exposure to thirdhand smoke (THS) as NNA is unique to THS. The NNA-dG covalent binding adduct could serve as such a biomarker, and play a role in identifying individuals exposed to THS, thus providing critical information for early detection and prevention.
    Type: Grant
    Filed: March 16, 2015
    Date of Patent: January 21, 2020
    Assignee: The Regents of the University of California
    Inventors: Bo Hang, Ahmed Chenna
  • Patent number: 10533057
    Abstract: The present disclosure relates to the treatment of multiple myeloma. Monoclonal antibody MOR202 is efficacious when administered to patient at certain dosage regimens.
    Type: Grant
    Filed: May 13, 2016
    Date of Patent: January 14, 2020
    Assignee: MORPHOSYS AG
    Inventors: Stéphane LeClair, Jan Endell, Stefan Härtle
  • Patent number: 10533052
    Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.
    Type: Grant
    Filed: June 25, 2018
    Date of Patent: January 14, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Xiao Min Schebye, Mark J. Selby, Michelle Minhua Han, Christine Bee, Andy X. Deng, Anan Chuntharapai, Brigitte Devaux, Huiming Li, Paul O. Sheppard, Alan J. Korman, Daniel F. Ardourel, Ekaterina Deyanova, Richard Huang, Guodong Chen, Michelle Kuhne, Hong-An Truong
  • Patent number: 10519236
    Abstract: Disclosed herein are antibodies specific to a delta1 chain of a ?? T cell receptor and methods of using such for modulating ?? T cell bioactivity. Such anti-Delta1 antibodies may also be used to treat diseases associated with ?? T cell activation, such as solid tumors, or for detecting presence of ??1 T cells.
    Type: Grant
    Filed: January 23, 2019
    Date of Patent: December 31, 2019
    Assignee: New York University
    Inventors: Shohei Koide, George Miller, Akiko Koide, Tatyana Panchenko
  • Patent number: 10517936
    Abstract: The present invention provides vaccines comprising carbohydrate antigen conjugated to a diphtheria toxin (DT) as a carrier protein, wherein the ratio of the number of carbohydrate antigen molecule to the carrier protein molecule is higher than 5:1. Also disclosed herein is a novel saponin adjuvant and methods to inhibit cancer cells, by administering an effective amount of the vaccine disclose herein.
    Type: Grant
    Filed: January 6, 2014
    Date of Patent: December 31, 2019
    Assignee: OBI Pharma., Inc.
    Inventors: Wei Han Lee, Nan-Hsuan Wang, Chung Hao Chang, Yih-Huang Hsieh, Cheng Der Tony Yu, Cheng-Chi Wang, Yu-Hsin Lin, Yu-Chen Lin, I-Ju Chen
  • Patent number: 10509035
    Abstract: This invention relates to antibody drug conjugates (ADC), antibody conjugates (AC) and novel antibodies. Particularly, the ADC, AC and antibodies disclosed herein specifically bind to the human anti-Müllerian hormone type II receptor (AMHR-II) and can be used to treat and/or identify AMHR-II expressing cancers, such as prostate cancer, breast cancer and gynecologic cancers expressing AMHR-II, such as ovarian cancer, in particular metastatic ovarian cancer, serous cancer, hypernephroma, endometrioid, colloidal epithelium, prostate cancer, germ cell cancer, endometrial cancer, mixed Müllerian malignant tumor of the uterus, leiomyosarcoma, or endometrial stromal sarcoma.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: December 17, 2019
    Assignee: GAMAMABS PHARMA SA
    Inventors: Olivier Dubreuil, Jean-Marc Barret, Jean-François Prost, Delphine Desigaud
  • Patent number: 10508149
    Abstract: The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to a protein encoded by the T Cell Immunoglobulin and Mucin Protein-3 (HM-3). The invention provides a TIM-3-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the TIM-3-binding agent to treat a disorder or disease that is responsive to TIM-3 inhibition, such as cancer, an infectious disease, or an autoimmune disease.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: December 17, 2019
    Assignee: AnaptysBio, Inc.
    Inventors: Marilyn Kehry, David J. King, Jean Da Silva Correia
  • Patent number: 10501744
    Abstract: The invention provides a fusion protein comprising an antigen binding domain linked to a bacteriophage decoration (Dec) protein along with a polynucleotide comprising the nucleic acid sequence of the fusion protein and a vector comprising the polynucleotide. Additionally, the invention provides a composition comprising the fusion protein and a virus-like particle (VLP), and a method of treating a disease in a mammal comprising administering a therapeutically effective amount of the composition to the mammal. The invention also provides a method of vaccinating against a disease comprising administering a composition comprising the fusion protein and a VLP encapsulating a protein.
    Type: Grant
    Filed: May 4, 2017
    Date of Patent: December 10, 2019
    Assignee: INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION
    Inventors: Trevor Douglas, Benjamin Harold Schwarz, Ranjit Koliyatt, Masaki Uchida, John Alexander Avera
  • Patent number: 10494444
    Abstract: Isolated antibodies that bind to human CD38 and cynomolgus CD38 are disclosed. Also disclosed are pharmaceutical compositions comprising the disclosed antibodies, and therapeutic and diagnostic methods for using the disclosed antibodies.
    Type: Grant
    Filed: September 13, 2017
    Date of Patent: December 3, 2019
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Kathleen Ann Elias, Gregory Landes, Shweta Singh, Wouter Korver, Andrew Walling Drake, Mary Haak-Frendscho, Gyorgy Pal Snell, Vinay Bhaskar
  • Patent number: 10493149
    Abstract: The present invention provides, among other things, stable formulations comprising an anti-oncostatin M receptor (OSMR) antibody and having a pH ranging from approximately 6.0-7.6, wherein less than approximately 5% of the anti-OSMR antibody exists as high molecular weight (HMW) species in the formulation.
    Type: Grant
    Filed: April 11, 2018
    Date of Patent: December 3, 2019
    Assignee: Kiniksa Pharmaceuticals, Ltd.
    Inventors: Mark Cornell Manning, Zahra Shahrokh, Dave Nichols, Phillip M Levesque, Ryan Erik Holcomb
  • Patent number: 10456420
    Abstract: This invention is directed to treatment of a subject having or suspected of having a cancer comprising administering to the subject a monoclonal antibody and NK-92 expressing Fc receptor.
    Type: Grant
    Filed: March 25, 2016
    Date of Patent: October 29, 2019
    Assignee: NantKwest, Inc.
    Inventors: Tien Lee, Hans G. Klingemann, Barry J. Simon, Laurent Boissel
  • Patent number: 10429390
    Abstract: The present invention relates to compositions and detection systems of antibodies or fragments thereof, wherein at least two antibodies or fragments thereof binds specifically to squamous cell carcinoma (SCC) and/or adenocarcinoma (ADC). Methods for using the antibodies in diagnosis, prognosis, and assessing efficacy of treatment is further included as well as kits including such compositions and detection systems.
    Type: Grant
    Filed: December 18, 2013
    Date of Patent: October 1, 2019
    Assignee: Biocare Medical, LLC
    Inventor: David Tacha
  • Patent number: 10407500
    Abstract: The present invention relates to an anti-Notch 3 antibody therapy useful for treatment of patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. In particular, the invention relates to an anti-Notch3 antibody or a fragment thereof having a 2 fold, 4 fold or 10 fold higher affinity to Notch 3 than to Notch 1 or Notch 2 for use in therapy.
    Type: Grant
    Filed: September 18, 2015
    Date of Patent: September 10, 2019
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Université Paris Didrerot—Paris 7
    Inventors: Anne Joutel, Søren Christensen, Thorleif Jan Pedersen
  • Patent number: 10407506
    Abstract: The invention provides anti-MCAM antibodies that inhibit the ability of human MCAM to bind a laminin alpha-4 chain. The invention also provides pharmaceutical compositions, methods of generating such antibodies, and their use in the manufacture of medicaments for treatment of neuroinflammatory disease, autoimmune disease, or cancer.
    Type: Grant
    Filed: March 12, 2015
    Date of Patent: September 10, 2019
    Assignee: PROTHENA BIOSCIENCES LIMITED
    Inventor: Yue Liu
  • Patent number: 10391170
    Abstract: The present invention provides, among other things, stable formulations comprising an anti-oncostatin M receptor (OSMR) antibody and having a pH ranging from approximately 6.0-7.6, wherein less than approximately 5% of the anti-OSMR antibody exists as high molecular weight (HMW) species in the formulation.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: August 27, 2019
    Assignee: Kiniksa Pharmaceuticals, Ltd.
    Inventors: Mark Cornell Manning, Zahra Shahrokh, Dave Nichols, Phillip M Levesque, Ryan Erik Holcomb
  • Patent number: 10370408
    Abstract: The present disclosure provides compositions and methods for purifying a protein such as DNase using a chromatographic process. The methods include a single chromatographic step and the use of high concentration salt buffers.
    Type: Grant
    Filed: June 25, 2015
    Date of Patent: August 6, 2019
    Assignee: JHL Biotech, Inc.
    Inventors: Gregory Scott Blank, Jiun-Liang Lin
  • Patent number: 10370440
    Abstract: The present invention provides modified fibronectin type III (Fn3) molecules, and nucleic acid molecules encoding the modified Fn3 molecules. Also provided are methods of preparing these molecules, and kits to perform the methods.
    Type: Grant
    Filed: April 30, 2015
    Date of Patent: August 6, 2019
    Assignee: Research Corporation Technologies, Inc.
    Inventor: Shohei Koide
  • Patent number: 10364289
    Abstract: The present disclosure relates to an antibody binding to Neuropilin 1 (NRP1) or an antigen-binding fragment thereof, a nucleic acid encoding the same, a vector comprising the nucleic acid, a cell transformed with the vector, a method for preparing the antibody or the antigen-binding fragment thereof, an antibody-drug conjugate comprising the antibody or the antigen-binding fragment thereof, and a composition thereof for preventing or treating a cancer.
    Type: Grant
    Filed: December 3, 2015
    Date of Patent: July 30, 2019
    Assignee: SAMSUNG LIFE PUBLIC WELFARE FOUNDATION
    Inventors: Do-Hyun Nam, Yeup Yoon, Jae Hyun Lee, Jin Ku Lee
  • Patent number: 10336818
    Abstract: The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index.
    Type: Grant
    Filed: August 13, 2014
    Date of Patent: July 2, 2019
    Assignee: Xencor, Inc.
    Inventors: Aaron Keith Chamberlain, Bassil Dahiyat, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar
  • Patent number: 10336822
    Abstract: This document provides methods and materials related to determining whether or not a human receiving a therapy (e.g., an anti-VEGF therapy such as a bevacizumab therapy) has developed or is at risk for developing proteinuria. For example, methods and materials for detecting urinary podocytes to determine whether or not a human receiving anti-VEGF therapy has or is at risk for developing proteinuria or kidney injury are provided.
    Type: Grant
    Filed: September 13, 2017
    Date of Patent: July 2, 2019
    Assignee: Mayo Foundation for Medical Education and Research
    Inventor: Vesna D. Garovic
  • Patent number: 10330650
    Abstract: The present invention relates to a high performance liquid chromatography method for polypeptide mixtures. Specifically, the method including the following steps: step (1): preparing a solution of the glatiramer acetate to be tested; step (2): performing gradient elution on a sample to be tested with an anion exchange liquid chromatography, a cation exchange liquid chromatography, or a reversed-phase liquid chromatography; step (3): determining a peak area corresponding to each component of the glatiramer acetate, comparing the peak area with to a peak area of a reference substance to determine whether the content of each component of the sample to be tested is in a qualified range.
    Type: Grant
    Filed: April 28, 2015
    Date of Patent: June 25, 2019
    Assignee: HYBIO PHARMACEUTICAL CO., LTD.
    Inventors: Yangming Tang, Gang He, Guotao Li, Anjin Tao, Jiancheng Yuan
  • Patent number: 10316327
    Abstract: An insect-resistant and/or fungi-resistant transgenic plant. The plant may be transformed with a gene construct including at least one gene chosen from LECRPA1, LECRPA2, and LECRPA3.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: June 11, 2019
    Inventors: Yi Li, Lisa Hollister
  • Patent number: 10308715
    Abstract: To provide a method of detecting abnormal bone metabolism by using a gene strongly expressed in an osteoclast; a method of screening a compound having a therapeutic and/or preventive effect on abnormal bone metabolism; and a pharmaceutical composition for treating and/or preventing abnormal bone metabolism. Provision of a method of detecting abnormal bone metabolism by using the expression of human Siglec-15 gene as an index; a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation; and the like.
    Type: Grant
    Filed: October 11, 2017
    Date of Patent: June 4, 2019
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Yoshiharu Hiruma, Eisuke Tsuda
  • Patent number: 10301389
    Abstract: Antigen binding constructs that bind to CD3, for example antibodies, including antibody fragments (such as minibodies and cys-diabodies) that bind to CD3, are described herein. Methods of use are described herein.
    Type: Grant
    Filed: June 13, 2013
    Date of Patent: May 28, 2019
    Assignee: IMAGINAB, INC.
    Inventors: David T. Ho, Tove Olafsen, Jason Romero, Christian P. Behrenbruch
  • Patent number: 10301388
    Abstract: Described herein are human antibody agents and multi-specific binding agents that specifically bind human CD 19, in particular, native human CD 19. Also provided herein are methods of using the same or compositions thereof for the detection, prevention and/or therapeutic treatment of diseases characterized by CD 19 expression, in particular, B cell lymphomas and leukemias.
    Type: Grant
    Filed: December 13, 2017
    Date of Patent: May 28, 2019
    Assignee: Eureka Therapeutics, Inc.
    Inventors: Hong Liu, Jingwei Lu, Zhiyuan Yang, Li Long, Neal Cheng
  • Patent number: 10273270
    Abstract: An object of the present invention is to create a novel engineered Protein A ligand having better antibody dissociation properties in the acidic condition compared with known engineered Protein A ligands. The present invention provides a protein having an affinity for an immunoglobulin, including an amino acid sequence obtained by introducing, into an amino acid sequence derived from any of E, D, A, B and C domains of Protein A, at least one amino acid substitution at any one or more of amino acid residues corresponding to positions 31 to 37 of the A, B and C domains (positions 29 to 35 of the E domain, positions 34 to 40 of the D domain), which are conserved in all the domains, the protein having a lower affinity for an Fab region of an immunoglobulin than a protein having the amino acid sequence before introduction of the substitution.
    Type: Grant
    Filed: March 24, 2011
    Date of Patent: April 30, 2019
    Assignee: KANEKA CORPORATION
    Inventors: Shinichi Yoshida, Dai Murata, Shunichi Taira, Masayuki Takano, Keita Iguchi, Yoshiyuki Nakano
  • Patent number: 10221245
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD19. The invention also relates to chimeric antigen receptor (CAR) specific to CD19, vectors encoding the same, and recombinant T cells comprising the CD19 CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a CD19 binding domain.
    Type: Grant
    Filed: March 15, 2014
    Date of Patent: March 5, 2019
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Jennifer Brogdon, Carl H. June, Andreas Loew, Marcela Maus, John Scholler
  • Patent number: 10206983
    Abstract: Provided are methods of enhancing an immune response and methods for reducing the recruitment of monocytes to a lymph node by administering to an individual an angiotensin II receptor blocker or a compound of Formula (I) in conjunction with an antigen. The invention also provides relate methods for amplifying vaccine immunity by administering to an individual an angiotensin II receptor blocker or a compound of Formula (I) in conjunction with an vaccine. The invention also provides related methods of inhibiting tumor growth and metastasis by administering to an individual with cancer an angiotensin II receptor blocker or a compound of Formula (I) in conjunction with an anti-tumor preparation. In addition, related compositions comprising an ARB or a compound of Formula (I) and an antigen, vaccine, or anti-tumor preparation are provided.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: February 19, 2019
    Assignee: COLORADO STATE UNIVERSITY RESEARCH FOUNDATION
    Inventors: Steven W. Dow, Daniel P. Regan, Amanda Guth, Leah Mitchell
  • Patent number: 10208109
    Abstract: The subject invention relates to monoclonal antibodies (e.g., 8F5 and 8C5) that may be used, for example, in the prevention, treatment and diagnosis of Alzheimer's Disease or other neurodegenerative disorders.
    Type: Grant
    Filed: July 21, 2011
    Date of Patent: February 19, 2019
    Assignees: ABBVIE INC., ABBVIE DEUTSCHLAND GMBH & CO KG
    Inventors: Heinz Hillen, Stefan Barghorn, Boris Labkovsky, Ulrich Ebert, Andreas R. Striebinger, Patrick Keller
  • Patent number: 10208120
    Abstract: The invention provides dual specific anti-FGFR2 and FGFR3 (FGFR2/3) antibodies, and compositions comprising and methods of using these antibodies.
    Type: Grant
    Filed: November 5, 2015
    Date of Patent: February 19, 2019
    Assignee: GENENTECH, INC.
    Inventors: Yiyuan Yin, Avi Ashkenazi, Paul J. Carter, Mark Chen, Junichiro Sonoda
  • Patent number: 10196452
    Abstract: The present disclosure provides isolated binding molecules that bind to the human OX40R, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions.
    Type: Grant
    Filed: November 8, 2017
    Date of Patent: February 5, 2019
    Assignees: Pfizer Inc., Bristol-Myers Squibb Company
    Inventors: Jing Min, Yanli Wu, Rory F. Finn, Barrett R. Thiele, Wei Liao, Ronald P. Gladue, Arvind Rajpal, Timothy J. Paradis, Peter Brams, Brigitte Devaux, Yi Wu, Kristopher Toy, Heidi N. Leblanc, Haichun Huang
  • Patent number: 10189896
    Abstract: The disclosure provides novel molecules related to growth and differentiation factor-8 (GDF8), in particular epitopes specific to GDF8 and other specific antagonists of GDF8 in particular anti-GDF8 antibodies or antigen binding protein or fragment thereof which may inhibit GDF8 activity and signal in vitro and/or in vivo. The disclosure also provides for an immunoassay used to detect and quantitate GDF8. The disclosure also provides methods for diagnosing, preventing, ameliorating, and treating GDF8-associated disorders, e.g., degenerative orders of muscle, bone, and insulin metabolism. Finally, the disclosure provides pharmaceuticals for the treatment of such disorders by using the antibodies, polypeptides, polynucleotides, and vectors of the invention.
    Type: Grant
    Filed: December 16, 2017
    Date of Patent: January 29, 2019
    Assignee: PFIZER INC.
    Inventors: Edward Roland LaVallie, Lisa Anne Collins-Racie, Christopher John Corcoran, Lioudmila Gennadievna Tchistiakova, John Adam Nowak, Riyez Karim, Xiang-Yang Tan, Kimberly Ann Marquette, Geertruida Machteld Veldman
  • Patent number: 10106600
    Abstract: The present invention relates to bispecific antibodies, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: March 24, 2011
    Date of Patent: October 23, 2018
    Assignee: Roche Glycart AG
    Inventors: Ulrich Brinkmann, Rebecca Croasdale, Harald Duerr, Christian Klein, Erhard Kopetzki, Wilma Lau, Joerg Thomas Regula, Juergen Michael Schanzer, Pablo Umana, Katharina Wartha
  • Patent number: 10100124
    Abstract: The present invention relates to binding proteins that bind to HER-3 and polynucleotides encoding the same. Expression vectors and host cells comprising the same for the production of the binding protein of the invention are also provided. In addition, the invention provides compositions and methods for diagnosing and treating diseases associated with HER-3 mediated signal transduction and/or its ligand heregulin.
    Type: Grant
    Filed: December 15, 2015
    Date of Patent: October 16, 2018
    Assignees: Daiichi Sankyo Europe GmbH, AMGEN, INC.
    Inventors: Mike Rothe, Martin Treder, Eric Borges, Susanne Hartmann, Larry L. Green
  • Patent number: 10094833
    Abstract: The invention relates to a novel antibody which binds to C-SLPI selected from the group consisting of SEQ ID NOs: 3 and 4.
    Type: Grant
    Filed: August 6, 2015
    Date of Patent: October 9, 2018
    Assignee: Randox Laboratories Limited
    Inventors: Clifford Taggart, Sinead Weldon, Chris Scott
  • Patent number: 10087250
    Abstract: The present invention relates to bispecific antibodies comprising at least two Fab fragments, wherein the first Fab fragment comprises at least one antigen binding site specific for a first antigen; and the second Fab fragment comprises at least one antigen binding site specific for a second antigen, wherein either the variable regions or the constant regions of the second Fab heavy and light chain are exchanged and the two Fab fragments are connected to each other by two peptide linkers; and wherein the bispecific antibody is devoid of a Fc domain; methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: October 3, 2013
    Date of Patent: October 2, 2018
    Assignee: Roche Glycart AG
    Inventors: Peter Bruenker, Tanja Fauti, Christiane Neumann, Christian Klein, Pablo Umaña